Although the genomic revolution has allowed a plethora of novel protein targets to be linked to disease states [1] [2] [3] [4] , standard small-molecule drug discovery strategies are unable to exploit all of these opportunities, because many of these potential targets do not have suitable binding pockets that directly modulate protein function 5 . Owing to their intracellular location, such proteins are often not tractable targets for antibody therapeutics either. The challenge that this presents for drug discovery is highlighted by the fact that there are very few marketed drugs that target scaffolding proteins, transcription factors and other non-enzymatic proteins inside the cell 6, 7 . Furthermore, small-molecule therapeutic strategies that focus on occupation of a binding site on a protein may require high systemic drug exposures to achieve sufficient site occupancy in vivo 8 and thus potentially increase the risk of off-target adverse effects.
. Owing to their intracellular location, such proteins are often not tractable targets for antibody therapeutics either. The challenge that this presents for drug discovery is highlighted by the fact that there are very few marketed drugs that target scaffolding proteins, transcription factors and other non-enzymatic proteins inside the cell 6, 7 . Furthermore, small-molecule therapeutic strategies that focus on occupation of a binding site on a protein may require high systemic drug exposures to achieve sufficient site occupancy in vivo 8 and thus potentially increase the risk of off-target adverse effects.
One method for modulating intracellular protein concentrations is through nucleic acid-based agents such as antisense oligonucleotides (ASOs) or agents that exploit RNA interference (RNAi), such as small interfering RNAs (siRNAs). More recently, the advent of CRISPR-Cas9 technology 9, 10 offers the potential of modifying the genome itself to achieve gene knockout; however, the clinical potential of this technology is yet to be explored (see recent reviews [11] [12] [13] ). Although nucleic acid-based tools have proved to be useful in research, the development of these agents as drug candidates has faced many challenges: unmodified nucleotides are highly unstable in serum 14 , whereas modified nucleotides tend to accumulate in the kidney 15, 16 and can be immunogenic 17, 18 . Nucleic acid-based agents encapsulated by nano particles to improve their delivery properties are still captured in the liver [19] [20] [21] [22] . In addition, RNAi can engage off-target mRNA, which leads to undesired effects [23] [24] [25] . Finally, efficacy is ultimately dependent on the target protein half-life; thus, long-lived proteins are less affected by these approaches. For a more detailed analysis, the reader is referred to these excellent reviews [26] [27] [28] . Although significant progress has been made, as indicated by the many ongoing clinical trials, only two ASO therapeutics (fomirisen 29 and mipomersen 30 ) that reduce the production of a particular protein have been approved in the United States 31 . Small-molecule-induced protein degradation is emerging as a strategy that also has the potential to target a broader range of proteins than standard small-molecule strategies that focus on binding site occupancy, yet maintain the pharmaceutical advantages that such compounds typically have compared with nucleic acid-based agents. This shift from inhibition of the target protein to its removal permits the targeting of proteins that have generally been considered 'undruggable' (REFS 32, 33) . Furthermore, removing 'druggable' targets from the system can be synergistic with current inhibitor-based regimens. For example, inhibition of certain cellular pathways promotes feedback-mediated increased expression of the target protein, which leads to pharmacological insufficiency 34, 35 . Induced protein degradation not only reduces the number of active proteins that need to be inhibited but also counteracts compensatory protein overexpression often observed upon loss of protein function. In addition, many druggable targets are recognized to have undruggable scaffolding roles that contribute to resistance mechanisms [36] [37] [38] [39] [40] [41] [42] . Induced protein degradation is not a recent concept. Inhibitors of the molecular chaperone heat shock protein 90 (HSP90), which helps other proteins to fold properly, first entered clinical trials in 1999. The initial excitement generated by HSP90 inhibitors was founded on the discovery that cancer cells upregulate HSP90 to drive proliferation and survival pathways 43 and are more sensitive to HSP90 inhibition owing to an overactive conformation of HSP90 found in cancer cells 44 . All reported HSP90 inhibitors target the ATP-binding domain [45] [46] [47] , thereby affecting HSP90 chaperone cycling and leading to degradation of HSP90 client proteins 48, 49 . There are more than 30 ongoing clinical trials associated with HSP90 inhibitors, yet none has gained approval from the US Food and Drug Administration (FDA)
. HSP90 inhibitors have been hindered by poor in vivo pharmacological properties and severe hepatotoxicity attributed to their benzoquinone moiety [50] [51] [52] . Furthermore, owing to the diversity of HSP90 client proteins, which constitute more than half of the human kinome [53] [54] [55] , it has been difficult to determine the exact cellular context in which an oncological vulnerability can be exploited by a broad inducer of protein degradation, although attempts have been made to bias the degradation 56, 57 . Several excellent reviews offer a more thorough survey of the HSP90 inhibitor literature [58] [59] [60] . In contrast to the general client protein knockdown achieved with HSP90 inhibitors, selective oestrogen receptor degraders (SERDs) and selective androgen receptor degraders (SARDs) exhibit high specificity in target protein degradation. Interestingly, these compounds were originally developed as modulators of protein function, but were subsequently serendipitously discovered to be protein degraders 61 . Although the efficacy of these compounds has been impressive, this strategy is not generalizable to other targets: the compounds can only induce the degradation of the oestrogen receptor (ER) and the androgen receptor (AR).
More recently, we and others have developed platform technologies that combine the modularity of nucleic acid-based strategies with the in vivo pharmacology of small-molecule therapeutics. Based on the concept of event-driven pharmacology, proteolysis-targeting chimaera (PROTAC) and hydrophobic tagging (HyT) technologies utilize bifunctional molecules, whereby one end binds to the protein of interest while the other end hijacks cellular quality control mechanisms to induce the degradation of the target protein (FIG. 1; TABLE 1 ). Only a transient binding event is required for activity, and thus, in contrast to the stoichiometric site occupancy of the occupancy-driven model, these event-driven molecules can cycle through multiple rounds of activity, removing sub-stoichiometric quantities of proteins. In addition, compared with the dissociation kinetics of an inhibitor from an active site, restoration of protein function requires re-synthesis of the protein, providing a kinetic advantage. Furthermore, the protein ligand does not need to occupy a binding site that affects protein function (such as the active site of an enzyme) in order to function as a degrader -binding at any 'nook' or 'cranny' on a target could potentially induce degradation. This advantage could be exploited by using thermal shift-, surface plasmon resonance (SPR)-or nuclear magnetic resonance (NMR)-based screens that focus on the identification of ligands that simply bind to a target, rather than screens that focus on identifying ligands that affect the function of the protein [62] [63] [64] [65] [66] . Moreover, by turning protein ligands into degraders, it might be possible to resurrect high-throughput screening (HTS) hits that bind to the desired targets but were set aside because they could not adequately block protein function [67] [68] [69] . Finally, several studies have determined that the degradation selectivity of PROTACs not only retains, but can also exceed, the binding selectivity of the protein ligand, such that PROTAC binding to off-target proteins does not necessarily lead to the degradation of the off-target protein; thus, PROTACs offer an added layer of specificity that can be modulated by which E3 ligase is recruited to the targets [70] [71] [72] . Substantial progress has recently been made, in particular with the development of PROTAC compounds, which has demonstrated that PROTACs are not just useful chemical tools but also viable therapeutic candidates. This progress also supports the idea that induced protein degradation is a novel drug discovery paradigm that has Box 1 | HSP90 inhibitors as broad inducers of protein degradation Geldanamycin 184, 185 , the first heat shock protein 90 (HSP90) inhibitor to be identified, exhibits low nanomolar activity against the US National Institutes of Health (NIH) panel of 60 cancer cells lines 186 . However, as a clinical agent, geldanamycin has poor solubility, is readily metabolized and is hepatotoxic 186 . Second-generation compounds tanespimycin (also known as 17-AAG) and alvespimycin (also known as 17-DMAG) have improved solubility but remain hepatotoxic [50] [51] [52] . Tanespimycin entered clinical trials in 1999 and -surprisingly -demonstrated good tolerability despite broad protein degradation 187 . More recently, in 2008, promising results were reported from phase II trials of tanespimycin for breast carcinoma (NCT00773344) 188 . However, phase III trials were not pursued by Bristol-Myers Squibb, probably owing to production and patent issues 58 . A third natural HSP90 inhibitor, retaspimycin (also known as IPI-504) entered phase III trials for gastrointestinal stromal tumour (GIST) in 2008 (NCT00688766), which were terminated owing to drug-related deaths 189 .
To address the solubility and hepatotoxicity issues of natural HSP90 inhibitors, synthetic inhibitors were pursued. CNF2024 (also known as BIIB021) 190 was the first purine-based inhibitor to enter the clinic (NCT00345189) and was found to be relatively effective against GIST in phase II trials (NCT00618319) 191 ; however, Biogen halted its development after discontinuing its oncology pipeline 192 . One of the most potent HSP90 inhibitors, NVP-AUY922 (REF. 193 ), entered multiple phase II trials for non-small-cell lung cancer (NSCLC), pancreatic cancer, GIST and breast cancer; however, Novartis recently halted all development of the compound. Ganetespib (also known as STA-9090) 194 also demonstrated some promise in a phase II trial for NSCLC 195 ; however, the following phase III trial (NCT01798485) was recently terminated owing to futility 196 . Identified through fragment-based drug discovery, onalespib (also known as AT13387) 197 has entered phase I/II trials for NSCLC and breast cancer (NCT02535338) after achieving limited efficacy for GIST 198 . the potential to target a broad range of proteins that are currently considered to be therapeutically intractable. In this Review, we summarize the main approaches that have been investigated so far to induce degradation of targeted proteins, highlighting the progress that has been made and discussing the opportunities and challenges in establishing drug discovery platforms based on these approaches.
Selective hormone receptor degraders
The ER, a nuclear hormone receptor, is one of the few transcription factors amenable to modulation with small-molecule drugs. Upon binding to oestrogens (17β-oestradiol, oestrone and oestriol), the ER binds to DNA to exert a cell-specific transcriptional response that is dependent on the co-regulatory proteins present 73 ; thus, oestrogens have a diverse effect on the cardio vascular, Figure 1 | Mechanism of induced protein degradation technologies. a | Hydrophobic tagging (HyT) using bifunctional adamantane-based molecules. One proposal for the mode of action is that the hydrophobic tag destabilizes the protein of interest (POI), thereby recruiting endogenous chaperones to the unfolded protein. The protein is then shuttled to the proteasome for degradation. An alternative proposal is that chaperones recognize the hydrophobic tag directly and mediate proteasomal degradation of the tagged protein. b | Proteolysis-targeting chimaera (PROTAC) technology works through active recruitment of an E3 ligase in order to tag proteins for disposal. Bifunctional PROTAC molecules bind to the POI with one end while the other end binds to an E3 ligase to form a ternary complex. The recruited E3 ligase then mediates the transfer of ubiquitin from an E2 enzyme to the POI. The ternary complex dissociates, the ubiquitylated POI is removed by the proteasome; and the PROTAC can bind to another POI (assuming the interaction with the POI is non-covalent). c | The traditional occupancy-driven pharmacology model is predicated upon stoichiometric drug binding to the POI in order to modulate protein function. With non-covalent inhibitors, the drug is capable of dissociating from the POI, leading to restoration of protein function. Furthermore, inhibitors based on occupancy-driven pharmacology typically bind to an active site on the POI (although allosteric inhibitors and inhibitors targeting protein-protein interactions are an exception). By contrast, induced protein degradation technologies are event-driven, and can potentially exploit binding anywhere on the POI in order to achieve degradation.
musculoskeletal, immune and reproductive systems in both males and females 74 . As ER signalling is crucial for breast cancer progression, ER-positive breast carcinomas are responsive to hormonal therapy, such as the selective oestrogen receptor modulator (SERM) tamoxifen 75 . However, depending on the cellular context, SERMs can function as either antagonists or agonists: in breast tissue, tamoxifen was found to act as an antagonist, whereas in the uterus, it was characterized as an agonist and led to an increased risk of endometrial cancers 76 . Furthermore, long-term oestrogen deprivation by SERMs can lead to compensatory feedback signalling, resulting in pharmacological insufficiency 77 . Addition of an alkylsulfinyl moiety to the endogenous ER ligand 17β-oestradiol led to the development of fulvestrant (also known as ICI 182,780) 78, 79 , which destabilizes the ER 61 (TABLE 1) . Upon binding to the ER, fulvestrant induces a structural change that leads to increased surface hydrophobicity and subsequent degradation 80, 81 . Degradation induced by fulvestrant affects the ligand-independent functions of the ER 82 that are not readily addressed by tamoxifen 83, 84 ; and fulvestrant probably has less risk of endometrial cancer than tamoxifen owing to its pure anti-oestrogen activity 85 . Thus, fulvestrant is the only FDA-approved SERD for ER-positive metastatic breast carcinomas that have progressed after tamoxifen therapy 86 . However, owing to fulvestrant's lack of oral bioavailability and poor systemic exposure 87, 88 , newer -generation SERDs are in development [89] [90] [91] [92] . Despite its issues, fulvestrant's limited clinical success prompted the pursuit of an analogous approach to target the AR in prostate cancer: that is, the development of SARDs. Like the ER, the AR is also a liganddependent transcription factor amenable to a traditional inhibitor approach. As a nuclear hormone receptor, the AR responds to endogenous androgens, including 5α-dihydrotestosterone (5α-DHT) and testosterone, in order to mediate the development and maintenance of male reproductive organs 93 . For this reason, prostate cancer is also initially dependent on AR signalling; thus, anti-androgen therapy with flutamide or bicalutamide has demonstrated good clinical efficacy for prostate cancer 94, 95 . However, resistance eventually develops, commonly through overexpression or amplification of the AR 35, 96 , leading to castration-resistant prostate cancer (CRPC) 97, 98 . A study using a more potent androgen antagonist, enzalutamide (which was approved by the FDA in 2012), established that a subset of CRPC is still dependent on androgen signalling 99 . To address these resistance mechanisms, a first-in-class nonsteroidal SARD, AZD3514 (REF. 100 ), was developed and was shown to downregulate the AR [101] [102] [103] . Despite promising phase I (NCT01162395) efficacy data 103 , the development of AZD3514 was discontinued owing to tolerability issues 104 . Although much work 105 has been done in the field of SARDs, there are currently no known SARDs on the market.
The field of induced ER and AR degradation remains active, with multiple compounds in clinical trials. Targeted degradation not only combats compensatory upregulation associated with inhibition of function but also affects functions not amenable to traditional inhibitors (that is, ligand-independent functions of the ER). However, SARDs and SERDs are only capable of inducing the degradation of the AR and the ER, respectively; they cannot be repurposed to target other proteins for degradation. (FIG. 2) . Similarly, dihydrofolate reductase was degraded using micromolar concentrations of the non-covalent inhibitor trimethoprim coupled to Boc 3 Arg. This induced target protein degradation pathway occurs via the proteasome in an ubiquitin-and ATP-independent manner, although the roles of chaperones and other quality control pathways remain unknown. Interestingly, it was recently found that the Boc 3 Arg moiety can inhibit the translational machinery as mediated by the mechanistic target of rapamycin complex 1 (mTORC1) pathway 108 . This off-target effect could potentially limit the clinical use of Boc 3 Arg as a hydrophobic tag.
An earlier HyT strategy, the adamantane-based HyT strategy, has been applied to a broader range of targets. This technology also consists of a bifunctional molecule, one end of which binds to a protein of interest and the other end engages quality control mechanisms through a hydrophobic adamantyl moiety 109 . First reported in 2011, ectopically expressed cytosolic and transmembrane HaloTag fusion proteins were shown to be susceptible to HyT-mediated degradation [110] [111] [112] . Pharmacokinetic studies with adamantane-based HyT in mice demonstrated that 75% of the hydrophobic tag remained in the mice after 24 h and that the HyT compound was sufficient to suppress xenografted HaloTag-HRAS-G12V-driven tumour growth in mice by 80% 110 . Immunoprecipitation of HaloTag fusion protein tagged with the adamantyl group demonstrated increased association with HSP70, suggesting that HSP70 mediates adamantylmediated degradation 113 . Furthermore, higher molecular weight bands corresponding to ubiquitylation were observed in the immunoprecipitates, suggesting that the ubiquitin-proteasome system (UPS) plays a part in adamantane-based HyT. In the same study, a second small-molecule ligand termed HALTS1 was shown to stabilize HaloTag fusion proteins, allowing for bidirectional control of protein levels 113 
. Despite the promising introduction of HyT technology as a tool for the modulation of intracellular protein levels, degradation of targets with HyT was only demonstrated via covalent interaction with the artificial HaloTag system at the time.
In 2014, the HyT technology was further extended to endogenously expressed proteins with the degradation of erythroblastosis oncogene B3 (ERBB3; also known as HER3), a pseudokinase considered to be undruggable by an occupancy-driven approach 114 . Gray and colleagues 115 discovered an ERBB3-selective covalent ligand from a HTS with an apparent IC 50 of 23 nM; however, given that ERBB3 has minimal kinase activity, a smallmolecule binder would have little effect on the scaffolding role of ERBB3. Coupling adamantane to the ERBB3 ligand, Gray and co-workers converted the ligand into a HyT degrader termed TX2-121-1. Covalent binding of TX2-121-1 to ERBB3 led to the degradation of ERBB3 at 500 nM, inhibiting downstream signalling and exhibiting an antiproliferative effect on ERBB3-dependent cell lines. Elimination of the covalent interaction reduced the efficacy of the adamantane-based HyT. The extension of the technology to the previously 'undruggable' ERBB3 was a significant step in the development of HyT as a therapeutic strategy; however, the degradation of ERBB3 was still dependent on a covalent interaction, and therefore the degradation pattern would be stoichiometric, rather than sub-stoichiometric.
Recently, our group has expanded the clinical potential of the HyT technology by targeting the AR with a non-covalent binder 116 . A high-affinity AR agonist, RU59063 (REF. 117), was coupled with an adamantyl moiety, thus converting an agonist into an antagonistic degrader. Upon incubation of LNCaP prostate tumour cells with the compound, AR degradation was observed in the sub-micromolar range, reducing the expression of AR target genes and leading to decreased cell proliferation. As the first demonstration of a successful adamantane-based HyT strategy with a non-covalent interaction, this study was a step towards expanding the range of targets for this approach. Despite this success, more examples of targets being degraded through a non-covalent interaction need to be demonstrated before HyT becomes a potential therapeutic strategy. Indeed, the in vivo potential of adamantane-and Boc 3 Arg-based HyTs in a non-artificial system remains untested.
The HyT platform illustrates the potential of a modular post-translational protein knockdown strategy by targeting traditionally intractable targets (such as ERBB3) or by utilizing non-covalent protein ligands to induce protein degradation. However, there is some concern that the hydrophobic moieties of such compounds can remain bound by serum proteins, which could result in a low free fraction of the compound available to induce degradation of target proteins. Moreover, it is unclear whether HyT-mediated degradation is dependent on the recognition of the adamantane or Boc 3 Arg moiety, or on the induced destabilization of the protein. If the latter, HyT would be less effective against more stable proteins, thereby limiting the number of targets that could be accessed for degradation. In addition, the degradation pathways for adamantaneand Boc 3 Arg-based HyT may be different. Thus, as the mechanism of HyT is unresolved, HyT technology remains a chemical tool for discovery biology rather than a viable therapeutic strategy. By contrast, PROTACs, which use small-molecule E3 ligase ligands to induce proximity-induced ubiquitylation of a target protein, are much closer to clinical translation. von Hippel-Lindau (VHL). The substrate recognition portion of the E3 ligase complex VHL-elongin B/C-cullin 2 (VHL-ELOBC-CUL2) that mediates the transfer of ubiquitin onto hypoxia-inducible factor 1α (HIF1α).
Poly-d-arginine tag
An arginine-containing peptide fragment based on the HIV Tat peptide that facilitates cellular uptake of proteins. (FIG. 1b) .
Occupancy-driven pharmacology
These early PROTACs were composed of a phosphopeptide portion of NF-κB inhibitor-α (IκBα) to recruit the F-box protein β-transducin repeat-containing protein (βTRCP; also known as FBW1A), a component of the S-phase kinase-associated protein 1 (SKP1)-cullin 1-F-box E3 ligase complex (SCF βTRCP ) 119 , and the angiogenesis inhibitor ovalicin to covalently bind to the target protein, methionine aminopeptidase 2 (MetAP2) 120,121 . The addition of this PROTAC to Xenopus egg extracts led to MetAP2 degradation. The potential of the technology was further demonstrated in a cellular system: the degradation of the AR was induced by microinjecting a βTRCP-based PROTAC with DHT as the protein ligand into HEK293 cells 122 . Although these were the first demonstrations of the PROTAC technology, there was much room for improvement: the potencies of these PROTACs were in the micromolar range and cellular permeability was very low; furthermore, the dependency on IκBα phosphorylation for E3 ligase recruitment was limiting given the action of cellular phosphatases.
The first improvement in peptidic PROTACs was a switch to a smaller E3 ligase-recruiting peptide fragment that did not require phosphorylation for activity. The E3 ligase von Hippel-Lindau (VHL) recognizes a core hydroxylated proline in a seven-amino-acid recognition sequence of hypoxia-inducible factor 1α (HIF1α) 123, 124 . An AR-targeting PROTAC was developed using DHT conjugated to the HIF1α peptide fragment with a poly-d-arginine tag appended for cell penetrance 125 . Addition of the PROTAC at a concentration of 25 μM led to significant AR depletion in HEK293 cells. Analogous PROTACs using oestradiol demonstrated ER degradation, which led to reduced proliferation of ER-dependent breast cancer cell lines [126] [127] [128] . More recently, VHL-recruiting peptidic PROTACs were used to induce the degradation of AKT 129 and tau 130 . The ability of PROTACs to induce degradation of a traditionally undruggable protein is among the advantages of event-driven pharmacology over occupancy-driven pharmacology (FIG. 1c) .
The advantage of event-driven pharmacology is further emphasized with the application of the PROTAC technology to the conditional removal of proteins. As the PROTAC technology works post-translationally (in contrast to nucleic acid-based approaches), there is a pharmacological opportunity to remove a select subset of proteins. Our group introduced a phosphorylationdependent PROTAC, whereby activation of the neurotrophin receptor TrkA or ERBB3 was coupled to the post-translational degradation of the downstream signalling components fibroblast growth factor receptor substrate 2α (FRS2α) and phosphatidylinositol 3-kinase (PI3K), respectively 131 . Upon growth factor stimulation, TrkA or ERBB3 phosphorylates a peptidic PROTAC, which is then recognized by either FRS2α or PI3K. FRS2α or PI3K, bound to their respective phosphorylated peptidic PROTAC, is then ubiquitylated by VHL. In a similar conditional knockdown study, the β-catenin-binding motif of epithelial cadherin was fused to βTRCP. The resulting fusion protein was capable of inducing the degradation of only the cytosolic population of β-catenin, sparing the membrane-bound population 132 . However, the potencies of these peptidic PROTACs remain in the micromolar range, probably owing to the poor cell penetration associated with peptide-based therapeutics. Fortunately, incremental improvements have led to the development of potent small-molecule PROTACs with in vivo stability. . PROTAC-induced AR degradation was observed at a concentration of 10 μM in cells; however, the maximum knockdown of the AR was not as strong as with the peptidic VHL ligand. Despite the success of this initial foray into all-small-molecule PROTACs, subsequent medicinal chemistry efforts were unsuccessful at achieving more effective degradation of the targets using the E3 ligase MDM2. However, newer generations of nutlins, such as RG7112 and idasanutlin (also known as RG7388), have been developed with increased potency 135, 136 , and it remains to be determined whether these can be successfully incorporated into PROTACs with improved potency and knockdown efficiency. Moreover, doselimiting cytopenias and gastrointestinal effects reported in phase I trials with idasanutlin are possible concerns for any nutlin-based PROTAC drug candidates 137 .
Another small-molecule-based PROTAC approach for targeted protein degradation, termed SNIPER (specific and non-genetic inhibitor of apoptosis proteins (IAPs)-dependent protein eraser), was reported in 2010 by the Hashimoto group 138 . Using bestatin (also known as ubenimex) esters 139 to repurpose the E3 ligase cellular IAP1 (cIAP1), Hashimoto and colleagues demonstrated the degradation of cellular retinoic acid-binding protein I (CRABPI) and CRABPII with all-trans-retinoic acid as the target ligand. Unfortunately, bestatin is not specific for cIAP1, as it inhibits both arginyl aminopeptidases and leukotriene A4 hydrolase 139, 140 . In addition, these bestatin esters induced the autoubiquitylation and degradation of the recruited E3 ligase cIAP1, limiting the full potential of the technology 141 . However, to overcome some of these limitations, medicinal chemistry efforts have reduced the autoubiquitylation observed with bestatin 142 or have recruited related E3 ligases for SNIPER 143 . In addition to the CRABP family, cIAP-based PROTACs were used to degrade the ER 144 , the AR 145 , retinoic acid receptors 145 and transforming acidic coiled-coil-3-containing protein 146 . Despite the range of targets degraded, SNIPER PROTACs are still maximally effective only in the micromolar range. Given the micromolar potencies of cIAP-based PROTACs and the fact that bestatin is not specific for cIAP1, SNIPER
PROTACs have yet to be tested in mouse models.
Recent efforts have focused on identifying an appropriate small-molecule replacement for the HIF1α peptide fragment to provide an alternative E3 ligase for the all-small-molecule PROTAC approach. The first small-molecule ligand (K d = 5.4 μM) for the VHL E3 ligase was identified through in silico and fragment-based screens in 2012 . This affinity is more than 20-fold weaker than a 10-mer HIF1α fragment interaction with VHL (K d = 0.2 μM). Subsequent structure-activity relationship efforts yielded a VHL ligand with a K d of 185 nM (REF. 150 ). Utilizing this improved ligand, a VHL-based small-molecule PROTAC was described in 2015 with nanomolar potency for nearly complete degradation of oestrogen-related receptor-α (ERRα) and receptor-interacting serine/threonine protein kinase 2 (RIPK2) without stabilization of the endogenous target HIF1α at concentrations of up to 30 μM of the ERRα-targeted PROTAC 70 . In vivo degradation of ERRα was achieved with approximately 40% knockdown of the protein in heart, kidney and tumour xenografts. Moreover, PROTACs demonstrated sub-stoichiometric effects: that is, one PROTAC molecule was capable of inducing multiple rounds of target protein ubiquitylation. Finally, through comparative proteomic studies, PROTACs were not only specific for the target protein but also had less off-target degradation than initially suggested by the ligand-binding specificity. This study was the first demonstration of a small-molecule VHL-based PROTAC with sub-stoichiometric activity and activity in mouse models.
Concurrent with the establishment of VHL-based PROTACs, another PROTAC system based on a fourth small-molecule E3 ligase-recruiting ligand was developed. In 2010, work from Handa and colleagues identified the E3 ligase cereblon (CRBN) as the primary target of thalidomide 151 . In 2014, the Kaelin and Ebert groups discovered that phthalimides (thalidomide, lenalidomide and pomalidomide) induced the degradation of the lymphoid transcription factors Ikaros family zinc finger 1 (IKZF1) and IKZF3 by binding to CRBN (K d = 150-250 nM) 155 and repurposing the E3 ligase to ubiquitylate the transcription factors. Further studies have found that not all of the phthalimides have the same substrate degradation spectrum and thus are utilized in different clinical situations: lenalidomide can induce the degradation of casein kinase Iα (CKIα), whereas thalidomide and pomalidomide are incapable of inducing CKIα degradation [156] [157] [158] . Recently, screening for CRBN ligands that degraded other targets led to the identification of CC-885, a phthalimide derivative that targets G1 to S phase transition protein 1 homologue (GSPT1; also known as ERF3A) 159 . Considering the ability of phthalimides to bind to CRBN, our group and others sought to utilize phthalimides as E3 ligase-recruiting ligands to hijack CRBN in order to degrade target proteins of interest. Conjugation of a small-molecule bromodomain-containing protein 4 (BRD4)-binding moiety (OTX015) to pomalidomide yielded a PROTAC capable of degrading the epigenetic regulator BRD4 at picomolar potencies 160 . In comparison to the BRD4 inhibitors JQ1 and OTX015, the CRBN-based PROTAC provided a more sustained suppression of MYC levels by counteracting known increased BRD4 expression associated with BRD4 inhibition 161 . This sustained suppression translated into superior antiproliferative and apoptotic effects of the PROTAC against Burkitt's lymphoma cell lines compared with the inhibitors. In a separate but parallel study, the BRD4 inhibitor JQ1 was conjugated to a thalidomide derivative 72 . The resulting PROTAC, termed dBET1, was capable of inducing BRD4 degradation at low nanomolar concentrations. Proteomic studies with this PROTAC determined that the compound significantly reduced MYC, BRD2, BRD3 and BRD4 levels with minimal off-target degradation. This bifunctional compound was also found to be superior to JQ1 against human acute myeloid leukaemia (AML) and lymphoma cell lines. Finally, dBET1 was investigated in a xenograft model of AML and a disseminated leukaemia mouse model; the PROTAC was found to be active in the AML model and outperformed JQ1 in the disseminated model. The superiority of event-driven versus occupancy-driven pharmacology in preclinical models is encouraging and sets the stage for clinical applications in the near future.
In addition to CRBN-based PROTACs, a picomolar VHL-based pan-BET-targeting PROTAC was developed, which demonstrated superior antiproliferative activity compared with BET inhibitors 162 . The pan-BET-targeting PROTAC also exhibited activity against a 22Rv1 CRPC mouse xenograft, thus
Box 2 | Induced protein instability for discovery biology
Several excellent reviews discuss the development of small-molecule-induced protein instability as a chemical biology tool 172, 176, 199 . However, two recent publications highlight the application of this chemical tool for discovery biology. In 2014, the hydrophobic tagging (HyT) technology was utilized to uncover an acute resolvable endoplasmic reticulum unfolded protein response (UPR) pathway that had previously evaded analysis using earlier chemical and genetic tools 200 . Cells expressing HaloTag fusion proteins localized to the endoplasmic reticulum were treated with adamantane-based HyT, leading to protein unfolding in the lumen of the endoplasmic reticulum. The stress induced by the hydrophobic tag was transient, resolvable and non-apoptotic in nature in comparison to the pro-apoptotic chemical tools thapsigargin 201 and tunicamycin 202 . This resolvable stress identified oestrogen signalling as a component of a late-stage endoplasmic reticulum stress resolution pathway.
In 2015, a similar small-molecule-induced protein instability technology elucidated a specific nuclear UPR distinct from the cytoplasmic heat shock response 203 . Furthermore, unfolding of a specific protein in the cytoplasm engaged a p53-dependent transcriptional programme that was not found in the general heat shock response. Cells primed with the inducible stress were more capable of surviving subsequent unfolded protein stress. These two studies highlight the advantages of chemical tools over genetic methods in terms of specificity, temporal control and dose-response for discovery biology.
Breakpoint cluster regionAbelson tyrosine kinase (BCR-ABL). An oncogenic fusion of BCR and ABL that can lead to chronic myeloid leukaemia.
expanding the application of PROTAC technology to solid tumours. Similarly, Ciulli and colleagues coupled the VHL-recruiting ligand to JQ1 to create a PROTAC that is capable of differentially degrading BRD4 over BRD2 and BRD3 (REF. 163 ). Maximum degradation of BRD4 occurred at nanomolar concentrations, although effects on BRD2 and BRD3 required low micromolar PROTAC concentrations. This selective degradation of BRD4 over BRD2 and BRD3 leads to a differential gene expression pattern between the parent inhibitor JQ1 and the BRD4-targeting PROTAC. This observation suggests that PROTACs can provide an added layer of specificity relative to an inhibitor: off-target proteins can be spared from PROTAC-induced degradation in spite of target binding.
This idea was further studied by exploring VHL-and CRBN-based PROTACs in a head-to-head comparison 71 . Utilizing the protein tyrosine kinase inhibitors bosutinib 164 and dasatinib 165 , PROTACs targeting the chimeric breakpoint cluster region-Abelson tyrosine kinase (BCR-ABL) oncoprotein and ABL were generated via conjugation to either a VHL-recruiting ligand or a CRBN-recruiting ligand. Surprisingly, the degradation profile of ABL-targeting and BCR-ABL-targeting PROTACs depended on the identity of the inhibitor warhead (bosutinib or dasatinib) and on the E3 ligase recruited (VHL or CRBN) but was independent of target engagement by the PROTACs. In this case, CRBN E3 ligase appeared to be more promiscuous in its degradation profile compared with VHL, consistent with previous studies targeting BRD4. One explanation could lie within the unique flexibility of the CRBN E3 ligase complex containing cullin 4A 157, [166] [167] [168] compared with that of the VHL E3 ligase complex 169, 170 , thus allowing for a larger ubiquitylation zone. These two studies into E3 ligase selectivity in the PROTAC system open up the possibility of converting a promiscuous inhibitor into a selective degrader.
With the progress made from the 2001 report of PROTAC-induced degradation in a Xenopus extract to the more recent targeted degradation achieved in cells and mouse models, interest in PROTACs has grown 171 . As a platform technology, PROTACs offer a modular 'plug-and-play' aspect that allows for general applicability: once a ligand for a target protein is identified, it can be linked to an E3 ligase-recruiting ligand for PROTAC development 172 . The removal of target proteins by PROTACs counteracts the compensatory accumulation of proteins that is often reported with inhibitors and provides a kinetic advantage similar to covalent inhibitors (that is, restoration of protein function requires target protein resynthesis). However, in contrast to the stoichiometric property of covalent occupancy-driven inhibitors, the event-driven catalytic nature of non-covalent PROTACs has the potential to require less total drug exposure. In addition, the possibility of conditional knockdowns and an increased layer of specificity hold the promise of minimizing off-target effects. Finally, proof-of-concept experiments in mouse tumour xenografts demonstrate that the in vivo efficacy of event-driven targeted protein degradation can be superior to the occupancy-driven pharmacology of the parent inhibitor compounds 160, 162 . The promise of induced protein degradation as a novel therapeutic modality has attracted the attention of the pharmaceutical industry 173 and has led to the creation of companies focused on developing such technologies. Arvinas (based in New Haven, Connecticut, USA) was launched in 2013 (REF. 174) and recently announced plans to advance a PROTAC-based drug candidate into phase I clinical trials in 2017 (REF. 175 ), and C4 therapeutics (based in Cambridge, Massachusetts, USA) was launched in 2016. Either as tool compounds 176, 177 or as a future drug discovery paradigm, the many potential applications of PROTACs have not yet been fully explored. However, from the few innovative reports to date, it is clear that induced protein degradation as a novel pharmaceutical paradigm holds much promise.
Challenges and opportunities ahead
With the progress made in the field of ASOs and the more recent publications in the field of small-moleculeinduced degradation, a complementary approach to the traditional therapeutic strategies inhibiting protein function -the modulation of protein levels -has emerged (FIG. 3) . Nucleic acid-based therapeutics initially held much promise with their ease of synthesis and modularity; however, dependency on protein half-life and challenging in vivo pharmacological properties have hindered the broad development of nucleic acid-based clinical drug candidates. General inducers of degradation, such as HSP90 inhibitors, have suffered from The ubiquitin-proteasome system (UPS) is the primary mechanism for removing misfolded proteins from the cytosol and nucleus. The UPS consists of a coordinated enzymatic cascade that results in the covalent attachment of ubiquitin (a 76-amino-acid protein) to a lysine residue of a targeted protein, eventually leading to the removal of this protein substrate by the proteasome. This cascade begins with an ubiquitin-activating enzyme (E1) 204 , which creates a reactive thioester on ubiquitin in an ATP-dependent manner. The ubiquitin is then transferred to the ubiquitin-conjugating enzyme (E2) 205 . The last enzyme, ubiquitin ligase enzyme (E3) 183 , specifically binds to the target protein and catalyses the proximity-induced transfer of the activated ubiquitin from the E2 protein to the target protein.
In order to regulate intracellular protein concentrations, E3 ligases recognize a number of degradation signals. For example, the E3 ligase von Hippel-Lindau (VHL) recognizes a core hydroxylated proline residue on hypoxia-inducible factor 1α (HIF1α) 124 whereas β-transducin repeat-containing protein (βTRCP) binds specifically to phosphorylated residues on NF-κB inhibitor-α (IκBα) and β-catenin 206 . A variety of E3 ligases are utilized in proteolysis-targeting chimaera (PROTAC) technology: cereblon (CRBN), VHL and βTRCP act as substrate recognition subunits in multisubunit cullin-ring E3 ligase (CRL) complexes 170, 183 , whereas mouse double minute 2 homologue (MDM2) forms homo-or hetero-oligomeric E3 ligase complexes for productive ubiquitylation 207, 208 . As ubiquitin has seven lysines, substrate-linked ubiquitin can be further modified to produce polyubiquitin chains with unique topographies. Ubiquitin chains linked through Lys48 have been classically associated with proteasomal degradation 209, 210 , whereas other chain types, such as Lys63 and Lys11, have been associated with subcellular localization, endocytosis and transcriptional regulation 211, 212 . By contrast, a single ubiquitylation event (monoubiquitylation) has been recognized to play a part in transmembrane protein endocytosis and signalling 213 . PROTAC technology tethers an E3 ligase to a target protein with the goal of inducing polyubiquitylation and subsequent removal of the target in the proteasome. 
Rule of five
The rule of five is a widely used guideline to predict the likelihood of poor absorption or permeability characteristics for small molecules. It is based on upper limits for physicochemical properties of the compounds, including molecular mass (for which 500 Da is the cut-off).
Degrons
Peptide segments recognized by the cellular quality control system that influence the degradation rate of the full-length protein.
challenging pharmacological properties, tolerability and the lack of a clear clinical indication; however, given the volume and range of ongoing clinical trials, HSP90 inhibitors may still find their way to the market. With the approval of fulvestrant, SERDs and SARDs remain another promising class of drugs that can address mechanisms of resistance arising from a traditional inhibitor approach. However, bioavailability and systemic exposure remain a challenge for this class of drugs. In addition, these small-molecule approaches are not broadly applicable to other targets. In theory, HyT technology can be applied to a broad range of targets, but the unknown mechanism of HyT might limit the adoption of the technology. By contrast, the PROTAC technology offers a modular approach to sub-stoichiometric targeted protein degradation, which only requires accessible surface lysines to be present on the target protein in order to harness the UPS
. However, PROTACs are not considered to be traditional 'small' molecules, as they do not conform to Lipinski's rule of five 178 owing to their relatively large molecular mass. Unfortunately, this larger size of PROTACs provides more opportunity for metabolic modification of the compounds. First-pass metabolism could limit the oral delivery of PROTACs, yet a lower bioavailability might not significantly hinder PROTAC efficacy given the sub-stoichiometric nature of the technology when using non-covalent ligands. In regard to future clinical application, the potencies achievable in cell culture as well as the efficacies observed in tumour xenografts are encouraging.
As the field of PROTAC-mediated target protein degradation matures, the idea of additional specificity could be explored further: is it possible to achieve tissue-or disease-specific induced protein degradation by utilizing tissue-or disease-specific E3 ligases? Smallmolecule screens have already identified several candidate E3 ligase inhibitors that can potentially be used as recruiting ligands [179] [180] [181] [182] , and our laboratory has found that different E3 ligases provide different degradation profiles 71 . A more thorough understanding of E3 ligase tissue expression could potentially offer an increased therapeutic window with an appropriate E3 ligaserecruiting PROTAC. Similarly, subcellular localization and regulation of E3 ligases could offer opportunities for conditional removal of target proteins 183 : perhaps an E3 ligase localized to the nucleus would permit conditional degradation of activated nuclear receptors while sparing the cytoplasmic population. In addition, as suggested by studies with peptidic phosphoPROTACs, perhaps developing 'state-specific' protein ligands will permit conditional protein knockdown; on the other end of the PROTAC, one can also imagine a conditional unmasking of the E3 ligase-recruiting ligand by either chemical or optical means to permit temporal and spatial control of target degradation analogous to the endogenous system of cryptic degrons. The concept of increased specificity is only the tip of the iceberg for this emerging technology.
Finally, PROTAC technology could have its biggest impact via the development of degrader molecules capable of targeting the undruggable proteome. Despite the recent success of small-molecule PROTACs, this technology has to date only been applied to classically druggable proteins. However, the ability to sub-stoichiometrically degrade transcription factors and scaffolding and other nonenzymatic proteins would greatly increase the current drug target space. One could envision a process in which appropriate protein binders are identified via screens and then conjugated to pre-made linkers attached to E3 ligase ligands to generate potent degrader compounds. In this way, PROTAC generation could become part of the routine strategy in drug discovery, thereby finally making the undruggable proteome pharmaceutically vulnerable.
